Last reviewed · How we verify
Micro-particle Curcumin
Micro-particle Curcumin is a Natural product derivative / Anti-inflammatory agent Small molecule drug developed by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. It is currently in Phase 3 development for Inflammatory bowel disease, Cancer-related inflammation. Also known as: Theracumin-Pro 300.
Micro-particle curcumin is a formulation of the natural polyphenol curcumin designed to improve bioavailability and enhance anti-inflammatory and antioxidant effects in the body.
Micro-particle Curcumin is a small molecule intervention being studied for the treatment of Chronic Kidney Disease in a clinical trial. Curcumin, also known as CI 75300, is a compound being investigated in this trial.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Micro-particle Curcumin |
|---|---|
| Also known as | Theracumin-Pro 300 |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
| Drug class | Natural product derivative / Anti-inflammatory agent |
| Modality | Small molecule |
| Therapeutic area | Inflammatory diseases / Oncology |
| Phase | Phase 3 |
Mechanism of action
Curcumin is the active compound from turmeric that exerts pleiotropic effects including inhibition of NF-κB signaling, reduction of pro-inflammatory cytokines, and antioxidant activity. The micro-particle formulation aims to overcome curcumin's poor oral bioavailability and rapid metabolism, allowing greater systemic exposure and tissue penetration for therapeutic benefit.
Approved indications
- Inflammatory bowel disease
- Cancer-related inflammation
Common side effects
- Gastrointestinal upset
- Nausea
- Abdominal discomfort
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Micro-particle Curcumin CI brief — competitive landscape report
- Micro-particle Curcumin updates RSS · CI watch RSS
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's portfolio CI
Frequently asked questions about Micro-particle Curcumin
What is Micro-particle Curcumin?
How does Micro-particle Curcumin work?
What is Micro-particle Curcumin used for?
Who makes Micro-particle Curcumin?
Is Micro-particle Curcumin also known as anything else?
What drug class is Micro-particle Curcumin in?
What development phase is Micro-particle Curcumin in?
What are the side effects of Micro-particle Curcumin?
Related
- Drug class: All Natural product derivative / Anti-inflammatory agent drugs
- Manufacturer: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's — full pipeline
- Therapeutic area: All drugs in Inflammatory diseases / Oncology
- Indication: Drugs for Inflammatory bowel disease
- Indication: Drugs for Cancer-related inflammation
- Also known as: Theracumin-Pro 300
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing